Table 1 Clinical cohort description

From: CD8+ TILs in necrotic tumors after neoadjuvant immunochemotherapy predict outcomes in non-small-cell lung cancer patients

Sex

Male

177 (88.5%)

Female

23 (11.5%)

Age (median = 63)

>65

75 (37.5%)

≤65

125 (62.5%)

Tumor type

Adenocarcinoma

40 (20%)

Squamous cell carcinoma

160 (80%)

Histological response

pCR

81 (40.5%)

MPR

37 (18.5%)

non-MPR

82 (41%)

Smoking status

ever

158 (79%)

never

42 (21%)

PD-L1

<1%

42 (21.0%)

1–49%

63 (31.5%)

≥50%

54 (27.0%)

Missing

41 (20.5%)

LN Metastasis (after therapy)

Yes

112 (56%)

No

88 (44%)

Stage

IB

35 (17.5)

II

50 (25%)

III

115 (57.5%)

Treatment cycle

1

6 (3%)

2

122 (61%)

3

51 (25.5%)

4

18 (9%)

5

3 (1.5%)

Back to article page